NOVEL SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS

1 . (canceled)

2 . (canceled)

3 . (canceled)

4 . (canceled)

5 . (canceled)

6 . (canceled)

7 . (canceled)

8 . (canceled)

9 . (canceled)

10 . (canceled)

11 . (canceled)

12 . (canceled)

13 . (canceled)

14 . (canceled)

15 . (canceled)

16 . A pharmaceutically acceptable salt of a compound according to Formula (I):

wherein the salt is a 1:1 free base/maleic acid salt.

17 . A pharmaceutically acceptable salt according to claim 16 , wherein the salt is in a crystalline form.

18 . A pharmaceutically acceptable salt according to claim 16 , wherein the salt exhibits peaks on a XRFD spectrum.

19 . A method for the prophylaxis and/or treatment of a condition selected from inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons, comprising administering an effective amount of a pharmaceutically acceptable salt according to claim 16 .

20 . The method according to claim 19 , wherein the pharmaceutically acceptable salt is administered in combination with another therapeutic agent.

21 . The method according to claim 19 , wherein the further therapeutic agent is an agent for the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

22 . A method for preparing a pharmaceutically acceptable salt of claim 16 comprising: combining the compound according to Formula I with maleic acid in an inert solvent; and precipitating said salt from said solvent.

23 . A method for preparing a pharmaceutically acceptable salt of claim 16 comprising: combining the compound of Formula I and maleic acid in a suitable solvent in order to achieve full dissolution; evaporating the solvent in order to achieve supersaturation; and crystallizing the salt.

24 . The method according to claim 22 , wherein the salt is obtained by mixing the compound of Formula I and the acid in a molar ratio of between 5:1 and 1:5 of Formula I: acid.

25 . The method according to claim 22 , wherein the solvent is selected from acetonitrile, dioxane, THF, acetone, DCM, and MeOH.

26 . The pharmaceutically acceptable salt according to claim 16 , obtainable by:

i) suspending 1 equivalent of the compound of Formula I in 20 volumes of 5% water in acetone at 25° C.,

ii) warming the suspension of step i) to 50° C.,

iii) adding 2.1 equivalent of maleic acid (1 M solution in THF) to the stirred suspension at 50° C. obtained in the previous step ii),

iv) cooling the mixture of step iii) to 25° C. at 1° C./min and stirring at 25° C. for 22 h,

v) separating by filtration the resulting solid obtained in the previous step iv),

vi) drying under suction said resulting solid obtained in the previous step v).